(Q47659326)

4 February 2018

title

Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. (English)

1 reference

4 February 2018

0 references

0 references

11

1 reference

4 February 2018

Jens Wiltfang

12

1 reference

4 February 2018

Juan Manuel Maler

4

Juan Manuel Maler

1 reference

4 February 2018

Piotr Lewczuk

1

Piotr Lewczuk

1 reference

4 February 2018

Hermann Esselmann

2

Hermann Esselmann

1 reference

4 February 2018

Udo Reulbach

10

Udo Reulbach

1 reference

4 February 2018

Andreas Wolfram Henkel

5

Andreas Wolfram Henkel

1 reference

4 February 2018

Maria Kerstin Henkel

6

Maria Kerstin Henkel

1 reference

4 February 2018

Markus Otto

3

Markus Otto

1 reference

4 February 2018

author name string

Oliver Eikenberg

7

1 reference

4 February 2018

Christof Antz

8

1 reference

4 February 2018

Wolf-Rainer Krause

9

1 reference

4 February 2018

publication date

1 March 2004

1 reference

4 February 2018

published in

Neurobiology of Aging

1 reference

4 February 2018

volume

25

1 reference

4 February 2018

issue

3

1 reference

4 February 2018

page(s)

273-281

1 reference

4 February 2018

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

1 reference

7 January 2021

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

The meaning and use of the area under a receiver operating characteristic (ROC) curve

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Evaluation and use of diagnostic tests in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2803%2900086-1

7 January 2021

10.1016/S0197-4580(03)00086-1

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018